**BRCA1** Haploinsufficiency Leads to Altered Expression of Genes Involved in Cellular Proliferation and Development

Harriet E. Feilotter¹,³, Claire Michel¹,⁴, Paolo Uy¹,⁴, Lauren Bathurst¹,⁴, Scott Davey¹,²,⁴*

¹ Departments of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada, ² Departments of Biomedical and Molecular Sciences and Oncology, Queen’s University, Kingston, Ontario, Canada, ³ Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada, ⁴ Division of Cancer Biology and Genetics, Queen’s University, Kingston, Ontario, Canada

Abstract

The assessment of **BRCA1** and **BRCA2** coding sequences to identify pathogenic mutations associated with inherited breast/ovarian cancer syndrome has provided a method to identify high-risk individuals, allowing them to seek preventative treatments and strategies. However, the current test is expensive, and cannot differentiate between pathogenic variants and those that may be benign. Focusing only on one of the two **BRCA** partners, we have developed a biological assay for haploinsufficiency of **BRCA1**. Using a series of EBV-transformed cell lines, we explored gene expression patterns in cells that were **BRCA1** wildtype compared to those that carried (heterozygous) **BRCA1** pathogenic mutations. We identified a subset of 43 genes whose combined expression pattern is a sensitive predictor of **BRCA1** status. The gene set was disproportionately made up of genes involved in cellular differentiation, lending credence to the hypothesis that single copy loss of **BRCA1** function may impact differentiation, rendering cells more susceptible to undergoing malignant processes.

Introduction

Breast cancer is one of the most common forms of cancer, and one of the leading causes of cancer-related deaths throughout the western world. While the majority of breast cancer cases are sporadic, 5–10% are classified as hereditary, and are due to the presence of a mutation in a breast cancer predisposition gene [1]. Approximately half of all hereditary breast cancers are due to a mutation in either **BRCA1** or **BRCA2**, and approximately 80% of individuals with a mutation in either of these genes develop breast cancer by the age of 70 years [2]. Because of the high risk of cancer in individuals with these mutations, their early and accurate identification targets them for increased surveillance and/or protective interventions such as surgery.

However, the task of identifying carriers of **BRCA** mutations is complicated by our continued lack of understanding of the specific biological mechanisms that are impacted by mutation of either gene. Additionally, the consistent evaluation of both **BRCA1** and **BRCA2** as a gene set implies that functional assays must necessarily be broad enough to capture activities of both proteins, an unreasonably difficult task. Therefore, we have chosen to focus on each of the genes as an independent problem to highlight the approach for development of a biological assay to explore loss of a complex protein. The work described here is focused on measurement of loss of **BRCA1** function.

Since the identification of **BRCA1** almost two decades ago [3], the molecular pathways in which **BRCA1** functions and how disruptions of these functions promote breast and ovarian carcinogenesis remains a mystery. The human **BRCA1** gene encodes an 1863 amino-acid protein, containing two highly conserved domains in the N- and C-terminal regions of the protein. At the N-terminus lies a RING domain, a cysteine rich zinc-binding motif that functions as an E3 ligase enzyme involved ubiquitination [4]. Two tandem repeat globular domains termed BRCT, a common feature of proteins involved in the DNA damage repair and cell cycle control [5], lie at the C-terminus. Functionally, **BRCA1** has been implicated in a diverse array of cellular functions, including ubiquitination [6–9], regulation of the G1/S [10], intra-S and G2/M-phase cell cycle checkpoint control [11–14], regulation of spindle pole body duplication[15], transcription [16–19], sex chromosome inactivation [20–23] and homologous recombination repair of double stranded DNA breaks [24,25]. Taken together, these individual roles suggest a function for **BRCA1** in the maintenance of genomic integrity [26,27]. **BRCA1** has also been suggested to play a role in the differentiation of breast epithelial cells, with loss of **BRCA1** function leading to impaired acini formation in 3D culture and an accumulation of less differentiated cells with altered proliferation properties [28–31].

Current methods for the identification of **BRCA1** carriers are based on gene sequence variations. One of the inherent difficulties
in this approach is in differentiating between clinically important changes and benign polymorphisms in these genes. While BRCA1 mutations that result in a truncated protein can usually unequivocally be called disease-causing, many other mutations, termed variants of unknown significance (VUS) are more difficult to interpret in a clinical context. Approximately 13% of BRCA1 and BRCA2 genetic tests reveal mutations identified as VUSs [32].

Tracking how specific BRCA1 mutations segregate with disease within families as well as case-control studies provide the most reliable information for classifying VUS as pathogenic or neutral. Case control studies are made difficult, however, by the rarity of specific mutations in the population, while segregation studies suffer from uncertainties generated by the high likelihood of phenoocopies among the affected, and the potential for late onset cancer in the unaffected. In cases where clinical data are not available to classify VUS, several functional assays have been developed to assess the effects of individual mutations on specific BRCA1 functions, including a transcriptional activation assay [33], phosphopeptide binding assay [34], ubiquitin ligase activity assay [35] and an embryonic stem-cell based functional assay [36]. However these functional assays can be technically complex and are limited to mutations in specific domains impacting particular functions. Regardless of whether the “correct” function is targeted in such assays, the requirement to assay multiple complex biochemical functions precludes the use of this approach in the clinical laboratory setting.

Given the pleiotropic roles of BRCA1, and the potential for individual mutations to lead to tumorigenesis via different mechanisms, the development of a functional assay for BRCA1 presents a significant challenge. However, because BRCA1 evidently plays a central role in many critical pathways that converge on the maintenance of genomic integrity, we hypothesized that there was a high likelihood that loss of even a single copy of BRCA1 would have a measurable impact on the expression of downstream genes involved in one or more of these pathways. Indeed, BRCA1 haploinsufficiency has been shown in several studies to alter the differentiation and proliferation pathways of breast epithelial/progenitor cells in patients carrying a BRCA1 mutation [30,31,37].

Evidence lending support to the idea of carrier-phenotype expression profiling comes from several studies, including small-scale studies on BRCA1 carrier fibroblasts following exposure to ionizing radiation (IR) [38,39]. Bellacosa et al. 2010 [40], showed that BRCA1 carriers had altered gene expression profiles in cultured primary breast and ovarian epithelial cells compared to non-carriers. Another recent study [41] showed that lymphocytes from BRCA1 mutation carriers demonstrated altered gene expression profiles following exposure to IR, which could be used as a prediction tool to identify BRCA1 mutation carriers. Here, we sought to determine whether EBV-transformed lymphoblastoid cell lines heterozygous for BRCA1 mutations could be distinguished from control cell lines using whole genome gene expression profiling.

Methods

Samples
EBV-transformed lymphocytes (LCLs) were obtained through the NIH Breast Cancer Family Registries. The 69 cell lines used in this study included 38 control (BRCA1+/+) and 31 BRCA1 mutation carriers (BRCA1+/-). The carrier cell lines included frameshift, missense, nonsense, and splicing mutations; a list of the BRCA1 mutations is shown in Table 1. All LCLs used in this study were cultured in RPMI-1640 media (Sigma Aldrich, Oakville, ON) supplemented with non-heat inactivated 15% fetal bovine serum (FBS) (Sigma Aldrich). All cell culture was carried out in 25 cm² flasks (Corning, Nepean, ON) at 37°C in 5% CO₂ atmosphere. Cells were split in a 2:1 ratio until the desired cell number of 650,000 cells/ml was reached. Where noted, DNA damage was induced through exposure to 2 Gy ionizing radiation (IR), delivered by a 137Cs Victoreen Electrometer (Atomic Energy of Canada, Mississauga, ON) at a dose rate of 0.52 Gy/min. Following treatment, the cells were allowed to recover for a period of 6 hr at 37°C in 5% CO₂ atmosphere prior to extraction of total RNA.

Ethics Statement
This work was approved by the Queen’s University Research Ethics Board under approval #PATH-115-10. Collection and generation of the LCL lines has been reported previously [42].

Cell culture and gene expression profiling controls
To assess the characteristics of our samples prior to transcriptional analysis, we determined the kinetics of arrest and recovery (0–18 h) across a range of IR doses (0–4 Gy). In all cases, cells were exposed to Cell Proliferation Labeling Reagent (Amersham Biosciences, Baie d’Urfe, Canada), according to the manufacturers instructions, for 1 hour prior to harvest. A dose of 2 Gy followed by 6 hours of recovery was the minimum dose and maximum recovery time at which we observed a uniform G1-S arrest, as assayed by loss of the early S phase cells from 2 dimensional flow cytometry profiles. This dose/recovery scheme was used throughout the study. For all microarray experiments, two parallel cultures were generated and one was treated with 2 Gy IR, 6 hours prior to harvest. Only cell lines showing proliferation in untreated cells, G1 checkpoint arrest following IR, and producing high quality RNA were used for microarray analysis.

Gene expression profiling
RNA from each of the 69 cell lines was extracted using TRIZOL Reagent following the manufacturer’s recommendations (Invitrogen, Burlington, ON). RNA was purified using the RNeasy MinElute Cleanup Kit (Qiagen, Mississauga, ON). RNA quality was assessed by Agilent 2100 Bioanalyzer (Version B.02.02). RNA with an integrity number of at least 7 was amplified and labeled using the Agilent Low RNA Input Linear Amplification kit (Agilent, Santa Clara, CA). Labeling reactions were performed with 250 ng total RNA, along with the Agilent Spike-in RNA mix, using Cy3-CTP and Cy5-CTP for control (-IR) and experimental (+IR) RNA, respectively (Perkin Elmer, MA, USA). Amplified RNA was quantified using the NanoDrop ND-1000 (NanoDrop Technologies, DE, USA) and the concentration of RNA and the specific dye activity were calculated. Samples with a specific dye activity greater than 5 pmol/μl were selected for hybridization to arrays. Pairs of cRNA (unirradiated versus irradiated) were hybridized to Agilent Whole Human Genome Oligo 4x4K GE arrays as per the product protocol. Image acquisition and analysis were done using an Agilent Microarray Scanner, Model G2565BA and Agilent Feature Extraction software v9.1 set to default settings. Raw data has been submitted to the NCBI GEO database (Accession Number GSE19541.)

Data analysis: Non supervised clustering
[NSC] analysis was done using the PAM method [43] as a software add-on within Microsoft Excel. Heat maps of the final classifiers, normalized by chip, were constructed using the Genesis software package [44]. Pathway analysis was performed using the
Identification of radiation responsive genes was done using SAM [45]. For NSC analysis, a total of 43,338 features were used in the analysis. 38 features that had gene label values that could not be interpreted by the analysis software were eliminated from the dataset prior to analysis. Normalization, where used, is described in the relevant sections of the Results.

Comparisons between microarray and qPCR data were calculated as follows: For microarray data, log (2) ratios between the values for each sample was compared to the average of all cell lines. For qPCR samples, \( \Delta C_t \) values were calculated for each target gene relative to the GusB control, and \( \Delta \Delta C_t \) values were calculated relative to the \( \Delta C_t \) value of WT19998 as a control. Fold changes were calculated individually versus the average of all cell lines for which data were available. Average values were calculated independently for each of the BRCA1 haploinsufficient and WT cell lines.

### Results

**Basal gene expression levels can be used to distinguish BRCA1+/− from BRCA1+/+ cells**

Following the generation of whole transcriptome expression data from each of the logarithmically growing cell lines, we sought to determine whether gene expression values differed in BRCA1+/− versus BRCA1+/+ lines. We used a nearest shrunken centroids analysis approach to analyze the data [43]. Data were analyzed either with no prior normalization, or following median normalization (per chip). These two approaches to analysis yielded similar and extensively overlapping results. However, the use of raw data tended to emphasize highly expressed genes, while the application of normalization algorithms permitted the identification of additional genes of interest that were expressed at lower levels. Therefore, we focused on the normalized datasets, although some genes unique to the non-normalized analysis were included in our final model.
We divided our samples into training (53 samples) and test (16 samples) randomly. Using the normalized data set, we observed the minimum training set error (6%, 3/53 samples) over a relatively wide range of shrinkage co-efficients (1.85–2.86), representing 288 to 23 genes, respectively. When this model was tested on the test set (8 wild type and 8 carriers), the accuracy was 95% (15/16), with a single misclassification of a control sample.

**Table 2.** List of genes identified as predicting BRCA1 carrier status.

| Gene   | Notes | Predictive Value | PCR Validated |
|--------|-------|------------------|---------------|
| PXDN   | 1     | 4.246558229      |               |
| JAKMIP2| 4     | 2.147236883      |               |
| MMP7   | 2     | 2.062558949      |               |
| CSRP2  | 1     | 1.797239311      |               |
| CD24   | 1     | 1.75716275       |               |
| LFGN   | 2     | 1.706805758      |               |
| ENPP2  | 2     | 1.705982587      |               |
| FOXP1  | 1     | 1.503455224      |               |
| PIWSP2 | 1     | 1.478776571      |               |
| PRLR   | 4     | 1.383493041      |               |
| IFNA5  | 4     | 1.228390716      |               |
| FCGRT  | 1     | 0.99756344       |               |
| IFNA4  | 1     | 0.99182988       |               |
| IFIT3  | 2     | 0.89448872       |               |
| SERPINF1| 2    | 0.86742073       |               |
| IGHD   | 3     | 0.84862378       |               |
| IFIT1  | 2     | 0.788035184      |               |
| ZBED3  | 2     | 0.786498412      |               |
| IFIT2  | 2     | 0.736255901      |               |
| USP18  | 3     | 0.727615739      |               |
| IFI44L | 2     | 0.693378004      |               |
| SOX4   | 2     | 0.471075432      |               |
| MX2    | 3     | 0.468182764      |               |
| MX1    | 3     | 0.462444907      |               |
| HLA-DMB| 3     | −0.378283622     |               |
| DUSP23 | 2     | −0.860935628     |               |
| GLDC   | 2     | −0.878929021     |               |
| ZBTB38 | 2     | −0.89526144      |               |
| BCR    | 2     | −1.004874472     |               |
| LAG3   | 3     | −1.068210822     |               |
| IL18BP | 2     | −1.173050671     |               |
| UBD    | 3     | −1.174177777     |               |
| TNS4   | 4     | −1.474875288     |               |
| SLC16A10| 4    | −1.558340909     |               |
| PLA2G4A| 1     | −1.62075284      |               |
| CYP1B1 | 2     | −1.779383571     |               |
| FAM79B | 1     | −1.900252217     |               |
| IFNG   | 4     | −1.97628822      |               |
| IGHG1  | 1     | −2.110861375     | Yes           |
| FYN    | 1     | −2.114129327     |               |
| CXCR3  | 1     | −2.203429664     | Yes           |
| TBX21  | 1     | −2.66823647      | Yes           |
| ETV7   | 2     | −2.720734937     |               |

The genes identified using the shrunken centroids analysis approach are listed. The list contains a total of 43 genes.

Notes: 1 means both from short list; 2 means both from long lists; 3 means raw only; 4 means normalized only.

doi:10.1371/journal.pone.0100068.t002
Modeling using the raw data was also effective, although it exhibited a slightly lower accuracy in the independent test set, and utilized a much larger number of genes in the predictor. The minimum training set error was 11\% (6/53), and accuracy on the independent test set was 88\% (14/16), with 2 control samples incorrectly classified, including the one that was previously misclassified using the model from the normalized data. The raw data model was accurate over a narrower range of shrinkage coefficients (1.35–1.65), representing 785 to 367 genes, respectively.

To generate a list of the most consistent predictive genes for biological analysis, we first selected genes that were identified by both approaches using the most stringent shrinkage coefficients (a total of 13 gene features). We then added genes that were ranked higher (by either model) than the lowest ranking of those identified by both approaches. In many cases, such genes were identified by both approaches if the shrinkage coefficients were relaxed to the lowest value that minimized training set error. A total of 17 genes were added by this approach. Finally, carrying out these approaches in both datasets (normalized or not) identified some genes that were only identified in the raw (7 genes) or normalized (6 genes) data sets. The end result was a list of 43 genes, summarized in Table 2.

To graphically examine the contribution of these candidates to the classification scheme, we used the GENESIS software package to generate a heat map of expression level of these 43 genes across the cell lines tested (Fig. 1). Samples are arranged by BRCA status at the top, with relative expression values at the right. As expected, clustering revealed distinct expression patterns in the training set. More importantly, this clustering was clearly recapitulated in the independent test set, indicating the classification results are consistent across the 43 gene profile, rather than being driven by a small number of genes within this set.

Genes predicting BRCA1 status indicate defects in interferon-regulated transcriptional pathways in BRCA1 haploinsufficient cells

To further understand the underlying biology leading to the classification scheme, we used the Ingenuity Pathway Analysis (IPA) application to explore the networks linking the genes in our predictor. IPA constructs optimal interaction networks that contain a maximum of 35 genes/proteins, and returns a graphical interaction network, as well as a calculated probability score. The probability score for any given network takes into account a number of factors, including the number of molecules on the input list that appear in the final pathway relative to random molecules in the database. The probability score for a network is calculated...
using a right-tailed Fisher's Exact Test [46]; and see www.ingenuity.com.

We developed a network based on the 43 gene consensus list (Fig. 2). The network is designated as relating to "Hematological System Development and Function," with a calculated p-value of $10^{-26}$. Of the 33 genes/complexes reported in this pathway by IPA, 20 are in our input list of 43, and an additional 9 components represent complexes containing these genes. The disease/disorder states identified as associated with the most genes in the 43 gene consensus list were cancer (26 genes, $p = 5 \times 10^{-3} - 7 \times 10^{-6}$) and inflammatory response (22 genes, $p = 5 \times 10^{-3} - 7 \times 10^{-6}$). The molecular and cellular functions associated with the most input genes were cellular growth and proliferation (26 genes, $p = 5 \times 10^{-3} - 7 \times 10^{-6}$) and cellular development (23 genes, $p = 5 \times 10^{-3} - 2 \times 10^{-7}$). The physiological system development and functions associated with the largest numbers of input genes were hematological system development and function (21 genes, $p = 5 \times 10^{-3} - 1 \times 10^{-7}$), and immune cell trafficking (15 genes, $p = 5 \times 10^{-3} - 1 \times 10^{-7}$).

An alternative approach to determining the function of genes that are differentially regulated in cells derived from BRCA1 carriers is through Gene Ontology analysis. Outputs from those analyses were in general agreement with the Ingenuity-based analysis, with the top GO Process terms identified including regulation of proliferation (12 genes: CD24, CXCR3, FOXP1, FYN, IFT3, IFNA4, IFNA5, IFNG, MMP7, PLA2G4A, SERPINF1, SOX4,) and differentiation (10 genes: CD24, CSR2P2, ETV7, FOXP1, IFNA4, IFNA5, IFNG, SOX4, TBX21, UBD.) In addition, other common GO process terms found among this list were the regulation of apoptosis (11 genes, CD24, CXCR3, FYN, IFT2, IFT3, IFNG, MX1, PRLR, SOX4, TNS4, UBD), cytokine-mediated signaling (10 genes: IFNA5, IFNA4, IFT1, IFT2, IFT3, USP18, MX1, MX2, HLA-DMB, IFNG), type 1 interferon-mediated signaling (8 genes: IFT1, IFT2, IFT3, IFNA4, IFNA5, MX1, MX2, USP18), response to virus (8 genes: TBX21, MX1, MX2, IFT1, IFT2, IFNA4, IFNA5, IFI44L), and immune response (6 genes: PXDN, ENPP2, FCGRT, IGHD, IGHG1).
Validation by qPCR

To ensure technical reproducibility, we validated a subset of the most highly predictive genes using qPCR. RNA was prepared from the indicated control and carrier cell lines, and subjected to TaqMan assay for the indicated target genes. Data were graphed along with the gene expression microarray data obtained in the original experiment. As presented in Fig. 3, CSCR3, TBX21 and IFIT1 all reproducibly show consistency between microarray and qPCR based approaches in terms of overall average values across multiple samples, as well as a generally consistent trend between individual samples. Of the 5 genes tested in this way, 4 were shown to recapitulate the microarray data in the followup qPCR assays (Table 2).

Differential response to radiation does not distinguish BRCA1+/− from BRCA1+/− cells

Given the association of BRCA1 with the DNA damage response, we also attempted to determine whether we could generate a molecular classifier to distinguish BRCA1 mutant heterozygotes from wild type cells following exposure of cells to IR. Analysis was performed using nearest shrunken centroids, essentially as above, except that expression for each gene was calculated relative to its own expression level in a parallel unirradiated sample. Training set error was minimized (9%) at a single shrinkage coefficient, 1.44, representing 144 genes. However, in this case, the predictive value of the model on the independent test set was poor. Only 5 of 16 samples (31%) were correctly predicted with multiple errors in both control and carrier prediction.

To optimize the modeling, the data were filtered to remove low expressing genes, which can cause difficulty in analysis. Using the 19650 genes with highest average expression level in control samples, analysis was repeated. Again, a single shrinkage coefficient, 1.57, representing 76 genes, was found, which minimized the training set error (15%). Analysis of the independent test set yielded an accuracy of only 5 of 16 samples.

It was unclear whether the failure to generate a predictor with this dataset was because the IR treatment had not had the desired effect, or whether activation of the DNA damage response did not differentiate between BRCA1 wildtype and haploinsufficient cells. To determine whether the IR treatment had actually had the desired effect on DNA repair and checkpoint pathways, we identified the radiation-responsive genes in wild type cells, and compared these to other published datasets [45,47,48]. Using SAM [45], with a defined false-discovery rate of 1.5%, we identified 2643 up-regulated genes (SAM score >1.26), and 3631 down-regulated genes (SAM score <−1.16), under the conditions described above. While a complete description of these results is beyond the scope of this manuscript, about half of previously reported radiation-responsive genes were recapitulated in our data set, suggesting appropriate activation of radiation response pathways following our treatment [Table 3].

Given this, we conclude that response to IR is unlikely to yield a functional discriminator for BRCA1 haploinsufficiency, and hypothesize that manifestation of the defect in radiation response may require loss of the second BRCA1 allele.

Discussion

Our results identify a set of dysregulated genes in unperturbed EBV-transformed lymphocytes carrying heterozygous BRCA1 mutations. The identity of the genes in our model is consistent with the hypothesis that cells with a reduced amount of functional BRCA1 are less differentiated than non-mutant control cells. In
addition, we have shown that subjecting the same cell lines to 2 Gy IR results minimal ability to discriminate cells carrying a BRCA1 mutation from those that do not. This suggests that BRCA1 haploinsufficiency does not cause global changes in the DNA damage response at low doses, but does not preclude such changes at higher doses. Alternatively, the DNA damage defects in BRCA1 mutant cell lines may only be seen after loss of the wild type BRCA1 allele. These findings together have significance for development of a functional assay for BRCA1 carriers, as well as for understanding the biology behind BRCA1-dependent breast cancers.

Apart from the potential clinical significance of a rapid functional tool to identify BRCA1 heterozygous mutation carriers, our model provides intriguing data about the biological effect of haploinsufficiency of this protein. TBX21 is one of the key genes we identified as down-regulated in BRCA1+/− LCLs compared to wildtype cells. It has been shown to act as a master regulator for T cell development, particularly via a mechanism involving interferon γ [49]. This finding is consistent with published work showing defective T cell lineage in BRCA1 null mice [50], and that BRCA1 is involved in the development of the breast in mouse and human systems [28,51]. In addition, breast tumors arising in BRCA1 carriers have been shown to have increased expression of several stem cell markers [52]. Consistent with this, we found that BRCA1+/− cells exhibited down-regulation of numerous interferon-regulated genes, including IFIT1, IFIT2, IFIT3, HERC5, and USP18. While neither IFNβ or IFNγ were identified in our predictive models for BRCA1 status, IFNγ is a component of the optimal SVM-based predictor, further supporting the idea that interferon signaling in general may be deregulated under conditions of BRCA1 haploinsufficiency.

Initial studies of LOH in the breast tumours of BRCA1 carriers reported a rate of 75% (75/101) of LOH of the wild type allele [53-56]. More recently, quantitative allelotyping has demonstrated a significant degree of variability in the extent and direction of LOH in breast tumours [57]. In some cases, normal tissue shows LOH of the wild type BRCA1 allele, and tumor tissue shows loss of the mutant allele.

In addition to the LOH studies, it is well established that complete loss of BRCA1 in sporadic cancer is a very rare event [58,59]. While this may reflect a different mechanism for BRCA1 inactivation in sporadic cancers, such as gene silencing, it may also be that BRCA1-dependent oncogenesis is initially associated with haploinsufficiency during development. This may be exacerbated by the additional cancer-driving effects of homozygous BRCA1 loss in the late stages of carcinogenesis contributing to the overall aggressiveness of BRCA1-dependent tumours. In such a model, BRCA1 would function as both a gatekeeper (early event due to haploinsufficiency leading to reduced differentiation) and a caretaker (later effect which requires complete loss of function, contributing to aggressiveness through effects on maintenance of genomic stability). Such a dualistic role might explain the bewildering lack of consistency of the LOH studies in BRCA1-related tumours to date.

This model of BRCA1 function may also explain our results that showed a relative lack of predictive power for discriminating BRCA1 carriers from wild type cells following irradiation. In contrast to previous finding using irradiated fibroblasts [38,39], our results from LCLs demonstrated that IR did not accentuate differences between wild type and BRCA1 mutation carrying cells. It is possible that these different results reflect fundamental differences in the radiation response between lymphocytes and fibroblasts.

The best model we generated was made using unirradiated cells. This is significant because it suggests that the best predictor may be achievable without the use of complicated irradiation protocols. Our model was 100% accurate in predicting the test set. There were a total of 8 samples in the training set that were not properly classified. Pooling of the test and training sets gave an overall sensitivity of 84% and a specificity of 92%. The ability to predict in an independent test set suggests that the model is robust and will likely be reproducible in further validation studies.

The accurate identification of BRCA1 mutation carriers is an important challenge in disease management. Given the size of the gene, the heterozygous state of individuals at risk, and multiplicity of functions ascribed to the protein, it is also a significant challenge to develop a comprehensive functional assay for BRCA1. The results of this study indicate that BRCA1 mutation carriers may be identified using a functional assay based on altered gene-expression profiles in non-cancerous cells. Furthermore, the ability of this assay to predict BRCA1 status in unperturbed cells suggests that it can potentially be adapted to a simple peripheral blood-based assay. Future work will focus on determining whether the gene expression patterns seen here can be observed in fresh blood samples as well, as this would be a condition of using this assay in a clinical screening setting. In addition, future work will also focus on whether the functional data from this assay can be applied to classifying VUS alterations in BRCA1; regardless of its utility as a screening tool, such a finding would add significant clinical value by appraising the likelihood of any VUS contributing to disease risk.

**Table 3. Comparison of overlap between this study, and other published gene expression microarray radiation response papers.**

| Study               | #ID’d | Overlap | Conditions | Array |
|---------------------|-------|---------|------------|-------|
| Tusher (2001)       | 36    | 20      | 5 Gy, 4 h  | 6.8k  |
| Jen (2003)          | 126   | 50      | 3/10Gy, 6-24 h | 12.6k |
| Rieger (2004)       | 200   | 106     | 5 Gy, 24 h | 12.6k |

doi:10.1371/journal.pone.0100068.t003
Author Contributions
Conceived and designed the experiments: CM PU LB. Analyzed the data: HF CM PU LB SD. Contributed reagents/materials/analysis tools: HF SD. Wrote the paper: HF CM SD.

References
1. Brody LC, Biesecker BB (1998) Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 77: 208–226.
2. Ford D, Easton DF, Stratton M, Nazif T, Goldgar D, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71.
4. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, et al. (1999) RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquination. Proc Natl Acad Sci U S A 96: 11364–11369.
5. Bock P, Hofmann K, Boucher P, Neuwald AF, Alschul SF, et al. (1997) A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. Faseb J 11: 68–76.
6. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, et al. (2001) The RING finger protein BRCA1-RING1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. The Journal of biological chemistry 276: 14357–14354.
7. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ (2002) Autoubiquitination of the BRCA1/RING1 ubiquitin ligase. The Journal of biological chemistry 277: 29305–29309.
8. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, et al. (2011) BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 479: 177–181.
9. Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, et al. (2004) BRCA1-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer research 64: 6644–6651.
10. Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, et al. (2002) BRCA1 supports Xist RNA concentration on the inactive X chromosome. Cell 111: 382–393.
11. Xu B, O'Donnell AH, Kim ST, Kastan MB (2002) Phosphorylation of serine 1387 in BRCA1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer research 62: 4308–4311.
12. Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286: 1162–1166.
13. Xu B, Kim S, Kastan MB (2001) Involvement of BRCA1 in S-phase and G2/M phase checkpoints after ionizing irradiation. Molecular and cellular biology 21: 3445–3450.
14. Yarden R, Pardo-Royo S, Spagias M, Coscan KH, Brody LC (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30: 285–289.
15. Xu X, Weaver Z, Linke SP, Li C, Gotay J, et al. (1999) Centrosome amplification and a defective G2/M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular cell 3: 389–395.
16. Scully R, Anderson SF, Chao DM, Wei Y, Ye L, et al. (1997) BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 94: 5605–5610.
17. Anderson SF, Schlegel BP, Nakajima T, Wolpin EN, Parvin JD (1998) BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 19: 254–256.
18. Montero AN, August A, Hanafusa H (1996) Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 93: 11595–11599.
19. Chapman MS, Verma IM (1996) Transcriptional activation by BRCA1. Nature 382: 678–679.
20. Ganeev S, Silver DP, Greenberg RA, Avni D, Drapkin R, et al. (2002) BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111: 393–405.
21. Ganeev S, Silver DP, Drapkin R, Greenberg R, Feunteun J, et al. (2004) Association of BRCA1 with the inactive X chromosome and XIST RNA. Philos Trans R Soc Lond B Biol Sci 359: 123–128.
22. Turner JM, Aprekova O, Xu X, Wang R, Kim S, et al. (2004) BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr Biol 14: 2135–2142.
23. Silver DP, Dimitriou SD, Feunteun J, Gelman R, Drapkin R, et al. (2007) Further evidence for BRCA1 communication with the inactive X chromosome. Cell 128: 991–1002.
24. Moynahan ME, Chiu JW, Kollier BH, Jain M (1999) Brca1 controls homology-directed DNA repair. Molecular cell 4: 511–515.
25. Moynahan ME, Cui TY, Jain M (2001) Homology-directed dna repair mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer research 61: 4842–4850.
52. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, et al. (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10.

53. Smith SA, Easton DF, Evans DG, Ponder BA (1992) Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2: 128–131.

54. Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, et al. (1995) High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 13: 203–210.

55. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, et al. (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9: 439–443.

56. Neuhausen SL, Marshall CJ (1994) Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer research 54: 6069–6072.

57. King TA, Li W, Brogi E, Yee CJ, Gemignani ML, et al. (2007) Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol 14: 2510–2518.

58. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120–122.

59. Sorlie T, Andersen TI, Bakshale I, Borresen-Dale AL. (1998) Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases. Breast Cancer Res Treat 48: 259–264.